133 related articles for article (PubMed ID: 11770272)
1. [(18F)-fluoro-2-deoxyglucose PET in imaging of gynecologic cancers].
Talbot JN; Grahek D; Kerrou K; Younsi N; de Beco V; Colombet-Lamau C; Petegnief Y; Cailleux N; Montravers F
Gynecol Obstet Fertil; 2001 Nov; 29(11):775-98. PubMed ID: 11770272
[TBL] [Abstract][Full Text] [Related]
2. [Role of [18F]-fluorodeoxyglucose positron emission tomography for the initial detection, staging, search for recurrences and restaging of gynaecological and breast cancers].
Grahek D; Barranger E; Daraï E; Uzan S; Talbot JN
Gynecol Obstet Fertil; 2005 Jun; 33(6):371-81. PubMed ID: 15927502
[TBL] [Abstract][Full Text] [Related]
3. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose.
Avril N; Dose J; Jänicke F; Ziegler S; Römer W; Weber W; Herz M; Nathrath W; Graeff H; Schwaiger M
J Natl Cancer Inst; 1996 Sep; 88(17):1204-9. PubMed ID: 8780629
[TBL] [Abstract][Full Text] [Related]
4. Value of whole body 18F-fluoro-2-deoxyglucose positron emission tomography in the evaluation of recurrent cervical cancer.
Sun SS; Chen TC; Yen RF; Shen YY; Changlai SP; Kao A
Anticancer Res; 2001; 21(4B):2957-61. PubMed ID: 11712793
[TBL] [Abstract][Full Text] [Related]
5. [Positron emission tomography (PET) with [18F]-FDG in bronchopulmonary cancer and its impact on medical decision at the time of diagnosis, staging, or recurrence evaluation].
Grahek D; Montravers F; Mayaud C; Regnard JF; Kerrou K; Younsi N; Talbot JN
Rev Pneumol Clin; 2001 Dec; 57(6):393-403. PubMed ID: 11924148
[TBL] [Abstract][Full Text] [Related]
6. PET imaging in gynecologic malignancies.
Kumar R; Alavi A
Radiol Clin North Am; 2004 Nov; 42(6):1155-67, ix. PubMed ID: 15488564
[TBL] [Abstract][Full Text] [Related]
7. Whole body positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer.
Yen RF; Sun SS; Shen YY; Changlai SP; Kao A
Anticancer Res; 2001; 21(5):3691-4. PubMed ID: 11848544
[TBL] [Abstract][Full Text] [Related]
8. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
9. PET imaging in breast cancer.
Bombardieri E; Crippa F
Q J Nucl Med; 2001 Sep; 45(3):245-56. PubMed ID: 11788817
[TBL] [Abstract][Full Text] [Related]
10. The role of PET scanning in the detection of recurrent cervical cancer.
Havrilesky LJ; Wong TZ; Secord AA; Berchuck A; Clarke-Pearson DL; Jones EL
Gynecol Oncol; 2003 Jul; 90(1):186-90. PubMed ID: 12821362
[TBL] [Abstract][Full Text] [Related]
11. Detection of recurrent colorectal carcinoma by 18F-FDG: comparison of the clinical performances of FDG PET and FDG CDET.
Montravers F; Grahek D; Kerrou K; Younsi N; Petegnief Y; de Beco V; Colombet-Lamau C; Talbot JN
Nucl Med Commun; 2004 Feb; 25(2):105-13. PubMed ID: 15154697
[TBL] [Abstract][Full Text] [Related]
12. Positron emission tomography scanning in gynecologic and breast cancers.
Zimny M; Siggelkow W
Curr Opin Obstet Gynecol; 2003 Feb; 15(1):69-75. PubMed ID: 12544505
[TBL] [Abstract][Full Text] [Related]
13. The role of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (18F-FDG-PET) in the diagnosis of recurrence and lymph node metastasis of cervical cancer.
Umesaki N; Tanaka T; Miyama M; Kawabe J; Okamura T; Koyama K; Ochi H; Ogita S
Oncol Rep; 2000; 7(6):1261-4. PubMed ID: 11032926
[TBL] [Abstract][Full Text] [Related]
14. FDG-PET for management of cervical and ovarian cancer.
Havrilesky LJ; Kulasingam SL; Matchar DB; Myers ER
Gynecol Oncol; 2005 Apr; 97(1):183-91. PubMed ID: 15790456
[TBL] [Abstract][Full Text] [Related]
15. [Utilization of PET scan in breast and gynaecologic cancers].
Huglo D; Vinatier D
Gynecol Obstet Fertil; 2004 Apr; 32(4):330-9. PubMed ID: 15123104
[TBL] [Abstract][Full Text] [Related]
16. Qualitative [18F]FDG positron emission tomography in primary breast cancer: clinical relevance and practicability.
Scheidhauer K; Scharl A; Pietrzyk U; Wagner R; Göhring UJ; Schomäcker K; Schicha H
Eur J Nucl Med; 1996 Jun; 23(6):618-23. PubMed ID: 8662094
[TBL] [Abstract][Full Text] [Related]
17. Whole-body PET with (fluorine-18)-2-deoxyglucose for detecting recurrent ovarian carcinoma. Initial report.
Yuan CC; Liu RS; Wang PH; Ng HT; Yeh SH
J Reprod Med; 1999 Sep; 44(9):775-8. PubMed ID: 10509300
[TBL] [Abstract][Full Text] [Related]
18. Imaging of gynecologic tumors: comparison of (11)C-choline PET with (18)F-FDG PET.
Torizuka T; Kanno T; Futatsubashi M; Okada H; Yoshikawa E; Nakamura F; Takekuma M; Maeda M; Ouchi Y
J Nucl Med; 2003 Jul; 44(7):1051-6. PubMed ID: 12843219
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of FDG PET in patients with cervical cancer.
Sugawara Y; Eisbruch A; Kosuda S; Recker BE; Kison PV; Wahl RL
J Nucl Med; 1999 Jul; 40(7):1125-31. PubMed ID: 10405131
[TBL] [Abstract][Full Text] [Related]
20. Axillary lymph node metastases: screening with [F-18]2-deoxy-2-fluoro-D-glucose (FDG) PET.
Adler LP; Faulhaber PF; Schnur KC; Al-Kasi NL; Shenk RR
Radiology; 1997 May; 203(2):323-7. PubMed ID: 9114082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
